Therapeutic formulations containing venom or venom Anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms

Abstract

A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 11 / 735,025 filed Apr. 13, 2007 (the entirety of which is incorporated herein by reference), which is a continuation of U.S. application Ser. No. 10 / 742,726 filed Dec. 19, 2003 (the entirety of which is incorporated herein by reference), which is a continuation of U.S. application Ser. No. 09 / 254,623, filed Jul. 8, 1999 (the entirety of which is incorporated herein by reference), which is the National Stage of PCT Application No. PCT / IB97 / 01091 filed Sep. 10, 1997 (which designated the U.S.) (the entirety of which is incorporated herein by reference), which claims the benefit of U.S. Provisional Application Ser. No. 60 / 025,179 filed Sep. 11, 1996 (the entirety of which is incorporated herein by reference).[0002]The present invention comprises the method of treating a host organism (man or animal) in need of a drug having direct or prophylactic anti-neoplastic activity comprisi...

AI Technical Summary

Benefits of technology

The anti-serum effectively inhibits tumour cell proliferation in vitro and in vivo, retarding neoplastic tissue growth without toxicity, and enhances immune responses by interacting with neoplastic cell membranes, thereby controlling the spread of tumours.

Problems solved by technology

Subsequent accumulation of lysophospholipids and free fatty acids promote damage to sarcolemmal membranes leading to irreversible cell injury and eventually cell death.

Images